Search

Your search keyword '"Peter Westervelt"' showing total 373 results

Search Constraints

Start Over You searched for: Author "Peter Westervelt" Remove constraint Author: "Peter Westervelt"
373 results on '"Peter Westervelt"'

Search Results

101. Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review

102. Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide

103. A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation

104. Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia

105. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant

106. Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning

107. A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome

108. Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation

109. Exome analysis of treatment-related AML after APL suggests secondary evolution

110. Bone Marrow Biopsy Needle Type Affects Core Biopsy Specimen Length and Quality and Aspirate Hemodilution

111. Mutation Clearance after Transplantation for Myelodysplastic Syndrome

112. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples

113. Comprehensive Characterization of Cancer Driver Genes and Mutations

114. Pan-cancer analysis of lncRNA regulation supports their targeting of cancer genes ineach tumor context

115. Genomic and functional approaches to understanding cancer aneuploidy

116. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily

117. Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation

118. Pathogenic Germline Variants in 10,389 Adult Cancers

119. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

120. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas

121. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

122. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

123. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines

124. The Immune Landscape of Cancer

125. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

126. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

127. Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

128. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia

129. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome

130. Myelodysplastic Syndromes, Version 2.2015

131. Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice

132. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

133. Do adults aged 70 years or older with acute myeloid leukemia benefit from allogeneic hematopoietic cell transplantation?

134. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer

135. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

136. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen

137. Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

138. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma

139. Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy

140. Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state

141. Targeted sequencing informs the evaluation of normal karyotype cytopenic patients for low-grade myelodysplastic syndrome

142. Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection

143. CpG island hypermethylation mediated by DNMT3A is a consequence of AML progression

144. Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML

145. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001

146. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802

147. A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma

148. Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia

Catalog

Books, media, physical & digital resources